To include your compound in the COVID-19 Resource Center, submit it here.

Cimzia certolizumab pegol: Phase II/III data

UCB disclosed in its 1Q11 earnings that Cimzia plus methotrexate met the co-primary

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE